Background: Type 2 (T2) inflammation drives airway dysfunction in many patients with asthma; yet, we lack a comprehensive understanding of the airway immune cell types and networks that sustain this inflammation. Moreover, defects in the airway immune system in patients with asthma without T2 inflammation are not established.
dendritic cells. Clustering of subjects within this network stratified subjects into T2-high and T2-low groups, but it also revealed a subgroup of T2-high subjects with uniformly higher expression of the T2 network. These "T2-ultrahigh subjects" were characterized clinically by older age and more severe airflow obstruction and pathologically by a second T2 network derived from T2-skewed, CD11b
1 classical dendritic cells. Subjects with T2-low asthma were differentiated from healthy control subjects by lower expression of a cytotoxic CD8
1 T-cell network, which was negatively correlated with body mass index and plasma IL-6 concentrations.
Of the 300 million patients with asthma worldwide, many respond well to available asthma treatments and experience minimal asthma-associated morbidity (1) . However, 5-10% have more severe disease that is resistant to current asthma therapies. These patients experience more frequent asthma exacerbations and significant disability (2) . Various pathobiologic mechanisms likely drive this heterogeneity in disease severity, and increased airway type 2 (T2) inflammation driven by the T2 cytokines (IL-4, IL-5, and IL-13) is the most established mechanism of asthma (3) . The majority of the understanding of the initiation and maintenance of airway T2 inflammation comes from murine asthma models that demonstrate epitheliumderived cytokines, such as TSLP (thymic stromal lymphopoietin) and IL-33, as activators of tissue-resident immune cells, such as type 2 innate lymphoid cells (ILC2), to produce large amounts of the T2 cytokines (3) (4) (5) (6) . Alternatively, few human studies have investigated which airway immune cell types underlie the persistent production of T2 cytokines in the airways of individuals with T2-high asthma. Thus, very little is known regarding how airway T2 inflammation is maintained in human asthma. Furthermore, even less is known regarding immune dysfunction in the approximately 40% of individuals with asthma who do not have T2 airway inflammation (7) .
One approach to advancing understanding of asthma biology is to study sputum cells, and sputum cells can be studied at both cellular and molecular levels. Indeed, we have shown the feasibility of extracting high-quality RNA from induced sputum cells (8) , and we have reported that many individuals with asthma have persistent expression of T2 cytokines despite treatment with inhaled or systemic corticosteroids (7) . These patients with steroid-refractory T2-high asthma are older and have more severe disease (7), but our prior sputum cell gene profiling work was PCR based, and the limited number of genes we studied did not reveal the gene expression networks that might explain disease severity in these patients. Furthermore, we were unable to determine the networks operating in patients with T2-low asthma.
Whole-transcriptome gene expression analyses have been conducted in sputum cell samples from individuals with asthma, and these studies have supported a role for eosinophilic, neutrophilic, and paucigranulocytic asthmatic disease (9, 10) . However, the multiple immune cell types that compose sputum samples have hindered a more comprehensive understanding of sputum expression patterns. In the present study, we used gene expression network analysis to decipher the immune cell types and mechanisms that underlie both T2-high and T2-low asthma.
Methods Cell Type-Specific Marker Gene Selection
We analyzed 12 flow-sorted immune cell gene expression profiles from the human Immunological Genome Project (Gene Expression Omnibus accession no. GSE3982) and the IRIS (Immune Response In Silico) Project (Gene Expression Omnibus accession no. GSE22886) (see Tables E1 and E2 in the online supplement). These data sets were combined using ComBat, a batch effect correcting tool in the sva package (11) . We proceeded to perform differential expression between each cell type and all other cell types using the limma software package (12) . For each cell type, we generated a random forest prediction model to identify the most important significantly upregulated genes that identify cell type; all genes with an importance value greater than 0 were kept (13, 14) . Owing to high similarity in the gene expression profiles of several immune cell types, we combined T cells with T-helper cells and mast cells with basophils. This left us with gene expression signatures for 10 purified immune cell types (Table E2) . To validate dendritic cell subtypes, we used gene expression data from purified murine lung dendritic cells obtained from the Immunological Genome Project database (15) .
Subjects and Sputum Sampling
The sputum RNA samples used in this study were acquired from the Airway Tissue Bank at the University of California, San Francisco. Subject characterization, sputum collection, and RNA extraction were performed using standardized and uniform protocols detailed in the online supplement (8, 16) .
RNA Sequencing
Bar-coded whole-transcriptome libraries were generated with the Ion AmpliSeq Transcriptome Human Gene Expression Kit (catalogue no. A26325; Life Technologies) according to the manufacturer's protocol. Sequencing data were generated with Ion Proton Sequencer (Life Technologies) using standard reagents and protocols. Read mapping was performed with TMAP (Torrent Mapping Alignment Program), and a read count table for each gene amplicon was generated using the Proton AmpliSeq plugin (Life Technologies). Sample sequencing depth was 10-14 million reads.
At a Glance Commentary

Statistical Methods
Using DESeq2 (17) , gene expression data were variance stabilizing transformation normalized. Multidimensional scaling analysis of the top 500 most variant genes (12) removed 10 outlier samples ( Figure  E1 ). Genes with fewer than 10 counts in 15% of samples were excluded from downstream analyses. This approach resulted in a final analysis dataset of 13,536 genes across 84 subjects with asthma and 27 healthy control subjects. Weighted gene coexpression analysis (WGCNA) was performed using a soft-threshold power of 12 and a deep-split metric of 3, and we obtained 24 coexpression networks (Table  E3 ). Eigengenes were calculated using the first principal component of all genes within each network. Using Spearman's correlation, we determined the association of these gene network eigengene values with each other and with other clinical traits.
Results
Specific Immune Cell Type-enriched Gene Sets
Gene expression data derived from induced sputum cells are a composite of expression from multiple immune cell types in the sample. To determine whether gene expression patterns identified from induced sputum are representative of changes in immune cell composition, we identified sets of genes enriched for specific immune cell types. These gene sets were developed by performing a combination of differential expression and feature selection analyses on published gene expression data (18) for 12 purified human immune cell types (Tables  E1-E2 ) (19) . Analysis of these gene sets by t-Distributed Stochastic Neighbor Embedding and plotting cells using two t-Distributed Stochastic Neighbor Embedding dimensions resulted in cell-type separation ( Figure 1A ). Moreover, ordering by cell types showed cellular specificity in gene expression profiles ( Figure 1B ).
Sputum RNA-Sequencing Networks Reflect Airway Immune Cell Diversity
Whole-transcriptome sequencing performed on the induced sputum samples from 27 healthy control subjects and 84 subjects with asthma identified 13, 536 expressed genes (Table E4 ). To identify coexpression networks, we performed WGCNA analysis on the subject-gene expression matrix, which identified 24 networks that we randomly assigned color labels (Figure 2A ). Enrichment analysis for immune cell-type gene sets revealed that at least 1 network was enriched for each of the 10 immune cell-type signatures tested, and 9 of the 24 sputum networks were significantly enriched for at least 1 cell-type signature ( Figure 2B ). For example, the turquoise network was highly enriched in genes specific for neutrophils ( Figure 2B ), and the dark green network was highly enriched in genes specific for eosinophils, basophils/mast cells, and monocyte-derived dendritic cells ( Figure 2B ).
To validate that our enrichment analyses correctly assigned cell types to their respective enriched networks, we correlated subject network expression with subject sputum cytospin cell counts. For example, we found strong correlations between the dark green network expression and eosinophil cell counts (r = 0.77), turquoise network expression and neutrophil cell counts (r = 0.746), and green network expression and macrophage cell counts (r = 0.669) ( Figure 2C ). These results reveal the diversity of immune cell types in the human airway and the utility of sputum gene expression network analysis to identify and quantify these immune cells. We tested each network's expression for association with asthma status and asthmarelated demographic variables ( Figure E2 ). The dark green network was most strongly associated with asthma, and expression levels of this network were 2.42-fold higher among subjects with asthma (P = 9.82 3 10 29 ) ( Figure 3A) . Moreover, dark green network expression negatively correlated with FEV 1 percent predicted (r = 20.35; P = 2.4 3 10 23 ) ( Figure 3B ) and positively correlated with biomarkers of airway T2 inflammation, including blood eosinophil cell counts (r = 0.67; P = 9 3 10 215 ) and fractional exhaled nitric oxide (FE NO ) concentrations (r = 0.52; P = 5 3 10 28 ) ( Figure E2 ). We found that all three T2 cytokine genes-IL4, IL5, and IL13-were present in this network and that the T2 cytokine gene mean (8) strongly correlated to dark green network expression (r = 0.86; P = 5 3 10 233 ) ( Figure 3C ). Therefore, we used the 92 genes in the dark green network to hierarchically cluster subjects into T2-high and T2-low asthma subgroups ( Figure 3D ). T2-high and T2-low clusters were identified on the basis of the first branching point in the dendrogram ( Figure 3D ). The T2-high cluster consisted of predominately subjects with asthma (n = 49) and few healthy control subjects (n = 2). The T2-low cluster consisted of nearly equal numbers of subjects with asthma (n = 35) and healthy control subjects (n = 25). Subjects with T2-high asthma had higher blood and sputum eosinophil concentrations, IgE concentrations, and FE NO concentrations, validating the clusterbased T2 status assignment (Table 1) . Hierarchical clustering also identified a subgroup of subjects with T2-high asthma with uniformly higher expression of genes in the T2 network ( Figure 3D ); we classified them as subjects with "T2-ultrahigh" asthma (n = 15) ( Figure 3D ). This T2-ultrahigh subcluster was characterized by higher blood and sputum eosinophil concentrations, FE NO concentrations, and T2 cytokine expression, but their IgE concentrations were not especially high (Table 1 and Figure  3E ). Furthermore, we found that subjects with T2-ultrahigh asthma were older (Table 1 and Figure 3F ) and had more severe airflow obstruction (Table 1) , despite the majority (11 of 15 [73%]) receiving inhaled corticosteroids (Table 1) .
Sputum T2 Inflammation Is Characterized by the Activity of Multiple Innate Immune Cells
Our immune cell enrichment analysis indicated that the sputum T2 network is derived from multiple innate immune cells, including eosinophils, mast cells/basophils, and monocyte-derived dendritic cells. To better understand the mechanisms underlying the genes in these immune cell enrichments, we examined the connectivity of the 92 T2 network genes using the WGCNA topological overlap matrix. Hierarchical clustering of these genes identified three highly correlated subsets of genes (labeled subnetworks 1-3) within the T2 network ( Figure 4 ). Subnetwork 1 contained all three T2 cytokine genes (IL4, IL5, IL13), together with three genes highly specific to mast cells/basophils (CPA3 [carboxypeptidase A3], HDC [histidine decarboxylase], MS4A2 [membrane spanning 4-domains A2]) and GATA2 (GATA-binding protein 2), a critical transcription factor in basophil and mast cell differentiation (20, 21) . We also observed three genes-NTRK1 (neurotrophic receptor tyrosine kinase 1), CST1 (cystatin SN), and CLCA1 (chloride channel accessory 1)-highly induced from airway epithelial cells by IL-13 stimulation (21, 22) . Subnetwork 2 contained the most interconnected genes in the T2 network ( Figure 4 ). CEBPE (CCAAT enhancer-binding protein epsilon) and GATA1, two genes with critical roles in eosinophil differentiation and maturation, were within this network (23) . Moreover, 17 of the 26 genes in this network were upregulated in sputum eosinophils after allergen challenge (P = 3.65 3 10 221 ) (24) . In addition, a hub gene in this network was IL1RL1 (IL-1 receptor-like 1), encoding the ST2 receptor for IL-33 cytokine signaling, a key signaling mechanism in T2 inflammation (25) .
Consistent with our enrichment, the genes in subnetwork 3 were highly representative of inflammatory dendritic cells (IDECs), including CD1A, CD1B, CD1C, CD1E, RAMP1 (receptor activity modifying protein 1), CD207, and F13A1 (coagulation factor XIII A chain) ( Figure 4 ). We also noted the presence of other IDEC markers in this subnetwork, such as the T2 chemokine CCL17 (C-C motif chemokine ligand 17) and FCER1A (Fc fragment of IgE receptor Ia) subunit of the high-affinity IgE receptor. Collectively, these data suggest that the T2 cytokine signal in the airways of patients with T2-high asthma is derived from the interaction of multiple innate immune cells, including eosinophils, mast cells/basophils, and IDECs.
An Activated T2-skewed
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subpopulations of cDCs (6, 29) driven by IRF4 (IFN-regulatory factor 4) and IRF8 (30), respectively. Both CD11B and IRF4 are part of the black network, and expression of these genes was highly correlated with black network expression ( Figure 5B ). In contrast, neither CD103 nor IRF8 was part of the black network, and expression of both genes was negatively correlated with black network expression ( Figure 5C ). To confirm these findings in a global analysis, we examined transcriptome-wide expression data for purified mouse lung CD11b
and CD11b 2 /CD103 1 dendritic cell populations. These murine gene sets were obtained from the Immunological Genome Project database (30) . Using gene set enrichment analysis (31), we found that black network genes were strongly enriched among the genes most highly expressed in CD11b Type 2  gene mean   SOCS2  LGALS12  PTGDR2   CLC   SIGLEC8  IL1RL1  GATA1   HDC   VSTM1  CEBPE  HRH4  GGT5  SPNS3  PRSS33  CAMK1   IL13   DACH1  GATA2  HRASLS5  TSPAN18  NKD1   RD3   SLC18A2  F13A1  LTC4S  CD1E  CD1B  CCL17  CD1C  P2RY2  GCSAML   IL4   NTRK1  SLFN13  FCER1A  ITGA9  MARCH3  CPA3  MMP10  PPP1R14A  CD1A  CD207  CYSLTR2  STARD4  CLEC4F  INPP1  WNT5A   IL5   GIPR  SLCO4C1  RUFY4  CLEC10A  PARM1  CALCRL  RAMP1  GPR35  SIAH2  CDK15  ITM2C  BCL7A  GPR82  MS4A2  C10orf128  CLCA1  TARP  KCTD15  SUSD3  CTNNAL1  EMR4P  SLC44A1  PYROXD2  SMAD7  MIR548I2  PKIB  TSEN54  OLFM2  SVIP  EDARADD  C17orf58  IGFBP6   AK2  IL9R   CST1  ZCCHC3  LDLRAD4  C11orf84  ADORA3  CYP2S1  UAP1  ABP1  SLC30A4 Figure 3 . Sputum transcriptome network analysis identifies a type 2 (T2) inflammation network that clusters subjects with T2-high, T2-ultrahigh, and T2-low asthma. (A, B) Eigengene values of the dark green network were robustly increased in subjects with asthma (black) compared with healthy control subjects (light gray) and were associated with lower FEV 1 values. (C) A summary metric of IL-4, IL-5, and IL-13 airway T2 gene expression (T2 gene mean) was strongly associated with the dark green network eigengene values. (D) Hierarchical clustering of subjects based on expression of genes in the dark green network resulted in three primary clusters. Cluster 1 was characterized by low T2 gene expression and contained an equal distribution of subjects with asthma (n = 35) and healthy control subjects (n = 25). Cluster 2 was characterized by high T2 gene expression and consisted predominately of subjects with asthma (n = 34) and few healthy control subjects (n = 2). Cluster 3 was characterized by extremely high T2 gene expression (T2-ultrahigh) and was comprised exclusively of subjects with asthma (n = 15). Black network eigengene values strongly correlated with dark green network eigengene values. (E) The T2 gene mean was robustly higher in subjects with T2-ultrahigh asthma. (F) Subjects with T2-ultrahigh asthma are characterized by older age. ICS = inhaled corticosteroids.
Functional enrichment analyses (32, 33) of black network genes identified
Gene Ontology categories involved in LPS-mediated signaling and its primary activation target, NF-kB (nuclear factor kB) ( Figure E3 ). In fact, all five NF-kB family members were located in the black network. LPS is a strong maturation stimulus for dendritic cells, and NF-kB signaling is required for dendritic cell development (34) . Enrichment analysis of black network genes also identified positive regulation of IL-2 production. IL-2 is produced by mature dendritic cells and stimulates T-cell expansion (35) . Taken together, our data suggest that this black network is tracking mature CD11b
1
/CD103
2 /IRF4 1 dendritic cell stimulation of T cells. This conclusion is further supported by the observation that the OX40 ligand (TNFSF4 [TNF superfamily member 4]) and the OX40 receptor (TNFRSF4 [TNF receptor superfamily member 4]) genes are in this network. The OX40 receptor is expressed only on activated rather than naive T cells, and likewise, OX40L is expressed only by activated dendritic cells (36) . Moreover, OX40L is expressed by a specific type of dendritic cell driving T-helper type 2 cell (Th2) differentiation (37 To identify immune mechanisms of T2-low asthma, we compared eigengene expression of each of the immune cell-enriched WGCNA networks between subjects with T2-low asthma (n = 35) and healthy control subjects (n = 27). We found that expression of the royal blue network was robustly lower in subjects with T2-low asthma than in healthy control subjects (false discovery rate, 0.03) (Table E5 ). Immune cell-type enrichment analysis identified the royal blue network as enriched for T-cell and natural killer cell genes ( Figure 2B ). Because CD8 1 cytotoxic T cells (CD8 1 T cells) express many of the same genes as natural killer cells, we analyzed the expression data for CD8
1 T-cell genes. Of the CD8 1 cell surface markers, we found that CD3E, CD3G, CD3D, CD8A, and CD8B (38) were all within the royal blue network and that their expression was strongly correlated with royal blue network expression ( Figure 6A and Table E3 ). Furthermore, many CD8 1 T-cell genes involved in cytotoxic function, including killer cell lectin-like receptors, PRF1 (perforin 1), and the granzymes, were identified as highly correlated members of the royal blue network (Figures 6B and 6C  and Table E3 ). Finally, we identified many additional CD8 1 T cell-associated genes in the royal blue network, including the CD8 1 T-cell transcription factors EOMES (eomesodermin) and TBX21 (T-box 21) (39, 40) as well as the cell surface markers CD40LG, CD96, NKG7 (natural killer cell granule protein 7), CD28, and IL12RB2 (IL-12 receptor subunit b2) (Table E3 and Figure 6D ). To confirm that the royal blue module was representing CD8 1 T cells, we used gene set enrichment analysis (31) to test overrepresentation of genes from the royal blue module in the (Table E2 ). This analysis confirmed that genes in the royal blue network were strongly enriched among the genes most highly expressed in CD8
1 T cells ( Figure 6E ). Interestingly, we found that the royal blue network was negatively associated with body mass index (r = 20.44; P = 1.58 3 10 26 ) ( Figure 6F ), with lower network expression levels in obese subjects with asthma than in nonobese subjects with asthma (P = 0.005) ( Figure  E4 ). Obesity induces a state of chronic low-grade inflammation characterized by elevated plasma concentrations of inflammatory cytokines such as IL-6, and we recently determined that this inflammation strongly associates with disease severity in asthma (41) . Thus, we assessed the relationship between the CD8 1 T-cell network and plasma IL-6 concentrations. We found a strong negative correlation between plasma IL-6 concentrations and expression of the CD8 1 T-cell network ( Figure 6F) . As a sensitivity analysis to determine if this observation was secondary to inhaled corticosteroids, we stratified subjects into those receiving or not receiving inhaled corticosteroids. We found that subjects with asthma who were not receiving inhaled corticosteroids demonstrated a similar negative correlation between CD8
1 T-cell gene expression and body mass index ( Figure E5 ). In concert, these findings suggest that expression of the CD8
1 cytotoxic T-cell network is decreased in individuals with T2-low asthma compared with healthy control individuals and that this decrease tracks with obesity and systemic IL-6 inflammation.
Discussion
The mechanism by which the airway immune system sustains persistent T2 cytokine production is poorly understood, and limited data exists for whether this inflammatory process is heterogeneous across individuals with T2-high asthma. To address this deficiency, we performed a complete characterization of the airway immune system by analysis of wholetranscriptome gene expression patterns generated from the sputum cell pellets of subjects with asthma and healthy control subjects. We found that the core T2 INPP1  UAP1  SVIP  AK2  C11orf84  EMR4P  C10orf128  STARD4  SUSD3  ZCCHC3  ADORA3  C17orf58  ABP1  SLC30A4  CXCR2P1  IL9R  ITM2C  PARM1  BCL7A  CTNNAL1  EDARADD  OLFM2  LTC4S  NKD1  P2RY2  SLCO4C1  MARCH3  PYROXD2  WNT5A  SIAH2  KCTD15  MMP10  CYP2S1  LDLRAD4  CLEC10A  F13A1  ITGA9  PPP1R14A  CCL17  CALCRL  PKIB  SLC44A1  RAMP1  CD1B  CD1E  CD207  CD1C  CD1A  FCER1A  CLEC4F  CLC  PTGDR2  LGALS12  GATA1  SOCS2  PRSS33  SIGLEC8  IL1RL1  RD3  HRASLS5  CEBPE  HRH4  CAMK1  CYSLTR2  TARP  GGT5  VSTM1  DACH1  SPNS3  TSPAN18  RUFY4  GPR82  IGFBP6  GPR35  MIR548I2  TSEN54  GIPR  SLFN13  GATA2  HDC  IL13  GCSAML  IL4  NTRK1  IL5  CPA3  SLC18A2  MS4A2  CDK15  CST1 (42, 43) . The IDEC signature includes the CD1 family genes that are involved in antigen presentation and the FCER1A gene subunit for the high-affinity IgE receptor, suggesting roles for these cells in both adaptive immune and IgE responses. Our workflow of sputum collection and RNA sequencing, coupled with unsupervised clustering of our core T2 network, represents a robust and unbiased method for classifying individuals with asthma as "T2 high" and "T2 low." Expression of these T2 network genes varied widely among the T2-high subgroup, and we found a subgroup of subjects with nearly uniformly high expression of all T2 network genes. These subjects with "T2-ultrahigh" asthma were older and had more severe airflow obstruction (7) despite the fact that they were usually receiving inhaled corticosteroids. These data suggest that not all airway T2 inflammation responds to inhaled corticosteroids, a finding that is consistent with our recent report of individuals with T2-high asthma who are older and whose asthma is nonresponsive to intramuscular triamcinolone (7). Our findings for a distinct T2-ultrahigh subgroup require confirmation in future studies of airway T2 inflammation and severe asthma.
Our analysis also revealed a cDC network that was increased in subjects with T2-high asthma, but especially in the T2-ultrahigh subgroup. This human airway cDC network clearly mirrored the welldescribed murine airway CD11b 1 /CD103 2 cDC population, which was shown to be a critical driver of the T2 immune response in mice (6, 30, 44) . Functional enrichment analysis of genes in this network demonstrated evidence of cDC activation via NF-kB signaling and upregulation of IL-2 production. Notably, the Gene Ontology signature for production of T cell-activating IL-2 and the presence of the dendritic cell ligand OX40 (TNFSF4) and the T-cell OX40 receptor (TNFRSF4) genes in this network leads us to conclude that this network captures key molecular events in the dendritic cell activation of Th2 cells (6, 30, 37) . The especially high expression of this network in the subjects with T2-ultrahigh asthma provides a potential mechanism underlying this severe disease subtype and a rationale for targeting CD11b 1 cDCs and/or the associated pathways in patients with T2-ultrahigh asthma.
The molecular mechanisms underlying T2-low asthma remain poorly understood. We found decreased expression of a network containing genes highly characteristic of CD8 1 cytotoxic T cells in T2-low asthma. A primary function of CD8 1 T cells is host defense against viral infection, and our data lead us to speculate that CD8 1 T-cell deficiency and an impaired immune response to viral infections could be a mechanism of exacerbations in T2-low asthma. Interestingly, we found that expression of this CD8
1 cytotoxic T-cell network was strongly related to obesity and systemic inflammation, and it is possible that obesity-related systemic inflammation could cause CD8
1 cytotoxic T-cell dysfunction, possibly via T-cell exhaustion (45) . Supporting this hypothesis, IL-6 concentrations were negatively associated with expression of the CD8 1 T-cell network, and genes specific for T-cell exhaustion, including PDCD1 (programmed cell death 1), LAG3 (lymphocyte-activating 3), and CTLA4 (cytotoxic T-lymphocyte-associated protein 4) (46), were in this CD8
1 cytotoxic T-cell network (Table E3) . The crosssectional nature of our study opens the possibility that our findings in T2-low asthma could be driven by the treatment effect of inhaled corticosteroids on airway inflammation. However, the strong negative association between body mass index and the CD8 1 T-cell gene network remained robust even in patients not receiving inhaled corticosteroids, suggesting that inhaled corticosteroid treatment was not responsible for this relationship.
We acknowledge limits to our use of gene expression proxies to infer the presence and quantity of specific cell types. Specifically, other cell types that were not represented in our analysis may also play a role in T2-high and T2-low disease. For example, mouse and human studies suggest that ILC2 cells are major producers of T2 cytokines. Using available mouse ILC2 cell data, we were unable to identify genes specifically enriched in ILC2 cells, preventing us from determining their contribution to the sputum T2 inflammatory signature. Moreover, gene profiles enriched in blood-derived immune cells used in our study may differ from these cells in the airway. Future studies employing single-cell sequencing of sputum cells will be needed to confirm and extend our results.
In conclusion, we demonstrate how gene coexpression network analysis in sputum cells can reveal airway immune cell dysfunction in asthma. Our work advances understanding of airway immune dysfunction in asthma and provides mechanistic targets for drug development in steroid-resistant T2-high and T2-low phenotypes of asthma. n Author disclosures are available with the text of this article at www.atsjournals.org. 
